Daniel M Schwartz
Engineers in San Francisco, CA
License number
Utah 122722-2202
Issued Date
Jan 1, 1911
Expiration Date
Nov 9, 1993
Category
Engineer/Land Surveyor
Type
Professional Engineer
Address
Address
San Francisco, CA
Organization information
See more information about Daniel M Schwartz at bizstanding.comUcsf Medical Center - Daniel M Schwartz MD
10 Koret Way RM K-301, San Francisco, CA 94143
Categories:
Ophthalmology Physicians & Surgeons
Phone:
(415) 353-2402 (Phone)
Professional information
Daniel Schwartz
Location:
San Francisco Bay Area
Industry:
Human Resources
Skills:
Career Development, Career Counseling, Leadership Development, Succession Planning, Employee Relations, Employee Counseling, Partnership Development, Workforce Planning, Team Building, Achieving Results, Vineyard Management, Farming, HR Consulting, Vineyard tour guide, Wine tasting, Wildlife adventures, Growing premium wine, Wine cellar lab testing, Grape destemming and crushing, Fermentation, Grape pressing, Barrel racking, Power washing, Wine Blending, Wine bottling, corking and labeling, Wine and food pairing
Senior Security Consultant At Hsm Electronic Protection Services, Inc.
Position:
SENIOR SECURITY CONSULTANT at HSM ELECTRONIC PROTECTION SERVICES, INC.
Location:
San Francisco Bay Area
Industry:
Security and Investigations
Work:
HSM ELECTRONIC PROTECTION SERVICES, INC.
-
SENIOR SECURITY CONSULTANT
Eye Treatments Using Synthetic Thyroid Hormone Compositions
US Patent:
6555582, Apr 29, 2003
Filed:
Aug 10, 1999
Appl. No.:
09/371592
Inventors:
Daniel M. Schwartz - San Francisco CA
John D. Baxter - San Francisco CA
Michele D. Jumper - SF CA
Thomas S. Scanlan - San Francisco CA
John D. Baxter - San Francisco CA
Michele D. Jumper - SF CA
Thomas S. Scanlan - San Francisco CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31195
US Classification:
514568, 514913, 424427, 424428, 424429
Abstract:
The present invention involves the discovery that synthetic thyroid hormones can be used as compositions to reduce intraocular pressure in vivo. Methods of screening synthetic thyroid hormones for effect on intraocular pressure, aqueous pressure, hydraulic conductivity, hyaluronic acid secretion, and extracellular matrix assembly are provided. Methods of treating glaucoma and treating excess intraocular pressure with synthetic thyroid hormones and compositions therefore are also provided.
Dynamic Motion Contrast And Transverse Flow Estimation Using Optical Coherence Tomography
US Patent:
7995814, Aug 9, 2011
Filed:
Jun 22, 2007
Appl. No.:
11/767187
Inventors:
Jeffrey P. Fingler - Pasadena CA, US
Scott E. Fraser - La Canada CA, US
Daniel Schwartz - San Francisco CA, US
Scott E. Fraser - La Canada CA, US
Daniel Schwartz - San Francisco CA, US
Assignee:
California Institute of Technology - Pasadena CA
The Regents of the University of California - Oakland CA
The Regents of the University of California - Oakland CA
International Classification:
G06K 9/00, A61B 6/00
US Classification:
382128, 378 4
Abstract:
The methods described herein are methods to ascertain motion contrast within optical coherence tomography data based upon phase variance. The phase variance contrast observes the nanometer scale motion of scatterers associated with Brownian motion and other non-flow motion. The inventive method of calculating motion contrast from the phase variance can differentiate regions of different mobility based on the motion contrast differences, and can use the phase information to characterize mobility properties of the scatterers. In flow regions, the inventive method for acquiring and analyzing motion contrast can identify the regions as well as characterize the motion. Furthermore, the inventive method can determine quantitative flow estimation, the index of refraction variations, and absorption variations within flow regions.
Local Administration Of Retinoids To Treat Deficiencies In Dark Adaptation
US Patent:
2008027, Nov 6, 2008
Filed:
Sep 30, 2005
Appl. No.:
11/576377
Inventors:
Daniel M. Schwartz - San Francisco CA, US
Mark E. Davis - Pasadena CA, US
Mark E. Davis - Pasadena CA, US
Assignee:
University Of Calfornia-San Francisco - San Francisco CA
International Classification:
A61K 31/07, A61P 27/02
US Classification:
514725
Abstract:
The present invention relates to improving, at least in part, a deficiency in dark adaptation for an individual. The therapy for dark adaptation includes local administration of a retinoid, such as a Vitamin A or a derivative thereof, such that deleterious side effects seen with systemic administration are avoided.
Biodegradable Peg Based Polymer Formulations In Ocular Applications
US Patent:
2003022, Dec 4, 2003
Filed:
Apr 10, 2003
Appl. No.:
10/410860
Inventors:
Daniel Schwartz - San Francisco CA, US
Keith Duncan - San Francisco CA, US
Jay Stewart - Fort Lauderdale FL, US
Keith Duncan - San Francisco CA, US
Jay Stewart - Fort Lauderdale FL, US
International Classification:
A61K031/765
US Classification:
424/078380
Abstract:
The present invention relates to methods and pharmaceutical compositions involving the use of bioerodible (biodegradable) polymers to address fundamental needs in ocular surgery including sealants and sealing methods, barriers to cellular adhesion and proliferation, and mechanical barriers. In a particular embodiment, the present invention is also directed to the treatment of intraocular hypotony in an eye by limiting the flow of aqueous from the eye. In a preferred embodiment, application of a polymer, such as to the angle of the eye, limits the flow, thereby increasing the intraocular pressure.
Lenses Capable Of Post-Fabrication Power Modification
US Patent:
7210783, May 1, 2007
Filed:
Jun 18, 2002
Appl. No.:
10/175552
Inventors:
Jagdish M. Jethmalani - Pasadena CA, US
Daniel M. Schwartz - San Francisco CA, US
Julia A. Kornfield - Pasadena CA, US
Robert H. Grubbs - South Pasadena CA, US
Christian A. Sandstedt - Pasadena CA, US
Daniel M. Schwartz - San Francisco CA, US
Julia A. Kornfield - Pasadena CA, US
Robert H. Grubbs - South Pasadena CA, US
Christian A. Sandstedt - Pasadena CA, US
Assignee:
California Institute of Technology - Pasadena CA
The Regents of the University of California - Pasadena CA
The Regents of the University of California - Pasadena CA
International Classification:
A61B 3/00
US Classification:
351219
Abstract:
The present invention relates to lenses that are capable of post-fabrication power modifications. In general, the inventive lenses comprise (i) a first polymer matrix and (ii) a refraction modulating composition that is capable of stimulus-induced polymerization dispersed therein. When at least a portion of the lens is exposed to an appropriate stimulus, the refraction modulating composition forms a second polymer matrix. The amount and location of the second polymer matrix may modify a lens characteristic such as lens power by changing its refractive index and/or by altering its shape. The inventive lenses have a number of applications in the electronics and medical fields as data storage means and as medical lenses, particularly intraocular lenses, respectively.
Treatment For Eye Disorder
US Patent:
8298521, Oct 30, 2012
Filed:
May 23, 2008
Appl. No.:
12/126100
Inventors:
Daniel M. Schwartz - San Francisco CA, US
Scott Fraser - Lacanada-flintridge CA, US
Robert H. Grubbs - South Pasadena CA, US
Justin P. Gallivan - Atlanta GA, US
Changjun Yu - Pasadena CA, US
Scott Fraser - Lacanada-flintridge CA, US
Robert H. Grubbs - South Pasadena CA, US
Justin P. Gallivan - Atlanta GA, US
Changjun Yu - Pasadena CA, US
Assignee:
The Regents of the University of California - Oakland CA
California Institute of Technology - Pasadena CA
California Institute of Technology - Pasadena CA
International Classification:
A61K 31/74
US Classification:
424 7804, 424 7802, 607 1, 607 88
Abstract:
The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch's membrane. An activating energy source is utilized to effect a controlled diffusion enhancement and/or degradation of Bruch's membrane that enables improved diffusional transport between the choroid and retina. The individual is administered an inactivated diffusion-enhancing molecule that becomes associated with the membrane, which is then precisely exposed to an activating energy source, such as light or ultrasound.
Ophthalmic Lance
US Patent:
5391177, Feb 21, 1995
Filed:
Feb 12, 1993
Appl. No.:
8/017508
Inventors:
Daniel M. Schwartz - San Francisco CA
International Classification:
A61B 1732
US Classification:
606167
Abstract:
An ophthalmic lance includes a retractable blade and a sheath, the retractable blade can only be exposed when a button is pressed down. The blade is attached to a spring loaded stem so that when the button is released, the blade is automatically retracted back into the sheath. Pressure on the button at the end of the stem or on the locking pin causes the blade to be exposed. As soon as that pressure is released the blade is automatically retracted back up into the sheath. The sheath has an H-shaped cutout in which a locking pin fits in and can slide about. The locking pin is coupled to the stem. The H-shaped cutout has a short-leg, a long-leg and a cross-bar so that when the locking pin is inside of the short-leg, the blade is in the locked position and when the locking pin is inside of the long-leg, the stem can be depressed and the blade exposed. To switch back and forth between the locked and the unlocked positions the stem must be rotated relative to the sheath so that the locking pin travels between the short-leg and the long-leg through the cross-bar of the H-shaped cutout.
Treatment Of Myopia
US Patent:
7727544, Jun 1, 2010
Filed:
May 9, 2005
Appl. No.:
11/124673
Inventors:
Daniel M. Schwartz - San Francisco CA, US
Chang Jun Yu - Pasadena CA, US
Robert H. Grubbs - Pasadena CA, US
Julia A. Kornfield - Pasadena CA, US
Scott E. Fraser - Lacanada-flintridge CA, US
Matthew S. Mattson - Pasadena CA, US
Chang Jun Yu - Pasadena CA, US
Robert H. Grubbs - Pasadena CA, US
Julia A. Kornfield - Pasadena CA, US
Scott E. Fraser - Lacanada-flintridge CA, US
Matthew S. Mattson - Pasadena CA, US
Assignee:
The Regents of the University of California - Oakland CA
California Institute of Technology - Pasadena CA
California Institute of Technology - Pasadena CA
International Classification:
A61F 2/00, A61K 31/74
US Classification:
424427, 424 7808
Abstract:
The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment and/or prevention of myopia. An activating energy source is utilized to photopolymerize or crosslink molecules in the sclera, thereby increasing the strength of the tissue. The individual is administered a crosslinking reagent or photopolymerizable molecule that becomes associated with the membrane, which is then precisely exposed to an energy source, such as light or ultrasound.